Ingredient Formulations of Category I drugs

@2336. CHOWDHARY RAM SEWAK : Will the Minister of IN-. DUSTRY be pleased to refer to answer to Unstarred Question 693 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) whether it is a fact that Category I drugs consist of single ingredient as well as multiple ingredient formulations;

(b) the names of the multiple ingredient formulations used for diseases under the National Health Programme;

(c) what is the composition of each drug and the disease for which each is used;

(d) on what basis the Ministry of Health and Family Welfare has come to the conclusion that Category-I drugs consist of single bulk drug only;

(e) whether it is a fact that the criteria for identification of Category I drugs is the therapeutic use of formulations;

(f) whether it is also a fact that Chloroquin and Tetracycline combination is being marketed in the country ;

(g) if so, what is the therapeutic use of this combination and whether this is used for Malaria; and

(h) what is the rationale behind decontrolling Oral Rehydration Salts when the same are" used for two National Health Programme ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS INTHE MINISTRY OFINDUSTRY (SHRI P. NAMGYAL) : (a) to (e) All multi ingredient formulations containing any of the bulk drugs specified in Schedule I of the DPCQ, 1987 fall under Category I of the DPCO, 1987.

(f) and (g) These details are not;. readily available.

(h) The Oral Rehydration Salt (ORS) has been price decontrolled on therecommendation ofthe Kelkar -Committee contained in their supplementary report.

©Previously Unstarred Question 1631, transferred from the 1st August, 1989.

Production of Drugs based on Oxyphenyl-Butazone and Phenylbutazone

@@2337. SHRL CHITTA BASU : Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of five leading brands- of drugs along with the names of producers based on Oxyphenyl-butazone and Phenylbutazone being marketed in India;

(b) what is the price of each brand of each drug;

(c) whether it is a fact that both these drugs have been kept outside price control on the plea of the representatives of the Ministry of Health and Family Welfare that these drugs are harmful and injurious and are being withdrawn shortly; and

(d) if so, what is the exact position of each drug; and what corrective steps are being taken in this regard ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS

@ ©Previously Unstarred Question 1638, transferred from the 1st August, 1989.